European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myelomaAccess, MyelomaAugust 28, 2019
Janssen seeks European marketing authorisation for subcutaneous (under the skin) daratumumab (Darzalex®)Access, MyelomaJuly 19, 2019
Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European CommissionAccess, MyelomaMay 23, 2019
Call to action for Central and Eastern European (CEE) members – join MPE CEE workgroup on accessAccess, MPEMay 6, 2019
Huge variations between countries in time for reimbursement decisions on new cancer drugsAccessOctober 20, 2018
